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Oncolytic immunotherapy with cytokine armed replica-
tion competent viruses is an emerging approach in can-
cer treatment. In a recent randomized trial, an increase in 
response rate was seen but the effect on overall survival is 
not known with any virus. To facilitate randomized trials, 
we performed a case–control study assessing the survival 
of 270 patients treated in an Advanced Therapy Access 
Program (ATAP), in comparison to matched concurrent 
controls from the same hospital. The overall survival of 
all virus treated patients was not increased over con-
trols. However, when analysis was restricted to GMCSF- 
sensitive tumor types treated with GMSCF-coding viruses, 
a significant improvement in median survival was present 
(from 170 to 208 days, P = 0.0012, N = 148). An even 
larger difference was seen when analysis was restricted to 
good performance score patients (193 versus 292 days, P 
= 0.034, N = 90). The survival of ovarian cancer patients 
was especially promising as median survival nearly qua-
drupled (P = 0.0003, N = 37). These preliminary data 
lend support to initiation of randomized clinical trials 
with GMCSF-coding oncolytic adenoviruses.
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INTRODUCTION
Following positive results in clinical trials, oncolytic viruses are 
nearing routine use in oncology. However, only one herpes virus 
has been studied in a randomized international phase 3 trial. Thus, 
although many different oncolytic viruses seem to have antitumor 
activity in cancer patients, their impact on survival remains mostly 
unknown. In oncology, it is widely accepted that reliable survival 
data can only be obtained in randomized trials. However, in the 
absence of such evidence, it might be of interest to attempt to esti-
mate the magnitude of effect. Furthermore, preliminary survival 
data might facilitate development of randomized studies, assist in 
power calculations, and perhaps suggest tumor or patient types 
most likely to benefit. Therefore, we performed a case–control 
analysis on cancer patients treated with oncolytic adenoviruses 
in an Advanced Therapy Access Program (ATAP), and compared 
their survival to similar patients not treated with virus. Subgroup 
analyses were performed on patients treated with viruses coding 
for granulocyte-macrophage colony stimulating factor (GMCSF), 
good performance score patients, and patients with tumors we 
thought likely (based on previous patient series)1–14 to respond to 
virus coding for GMCSF. Exploratory analyses were performed in 
different tumor types.
RESULTS
GMCSF-sensitivity of various cancer types
This case–control study consists of 270 cases and 186 controls from 
the same hospital and same time period, collected according to 
cancer type and disease phase (i.e., refractory to standard therapy). 
Based on previous analyses of ATAP patient series, we suspected 
that certain tumor types were more sensitive to treatment with 
GMCSF-coding viruses than others.1–14 To formally evaluate this, 
all 270 ATAP patients with survival information were grouped 
according to tumor types, and some of the more rare tumors were 
grouped together according to organ type (Table 1). Then, focus-
ing on patients that had been treated with GMCSF-coding viruses, 
including the great majority, tumor types were ranked according 
to signs of treatment benefit in imaging analysis, defined as dis-
ease control rate, meaning stable disease or response in patients 
progressing prior to therapy. Tumor types featuring >30% dis-
ease control rate were categorized as GMCSF-sensitive while the 
remainder were classified as non-GMCSF-sensitive (Table 2). Of 
note, GMCSF-sensitivity was determined based on imaging, and 
then overall survival was studied as the study endpoint. In immu-
notherapy, there has been a disconnect between imaging results 
and survival data15,16 and therefore we did not take for granted 
that these aspects were linked. De facto, survival analysis was per-
formed blinded with regard to imaging data thus constituting an 
independent prospective assay.
Comparability of patients and controls
To evaluate if there was imbalance between cases and con-
trols potentially affecting survival data, we analyzed the key 
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baseline variables possibly relevant in the context of overall 
survival (Supplementary Table S2). The comparison was done 
both according to cancer type and also for all cancer types com-
bined. Furthermore, patients treated with GMCSF-expressing 
viruses were analyzed separately (Supplementary Table S3). 
In general, most baseline variables were evenly distributed 
between cases and controls. However, controls were slightly 
older while cases had received more previous therapy (Table 1, 
Supplementary Table S2). If the distribution was uneven, the 
effect of the variable on overall survival was further analyzed 
with log rank-test (data not shown). While there were some 
baseline variables which were unevenly distributed, as expected 
due to chance, the only combination of baseline variable with 
tumor type with significant impact on survival was in neuro-
endocrine cancer type (log rank P = 0.039). Here, overall sur-
vival was in favor of older patients and as the control group 
for this tumor type consisted of older patients (Supplementary 
Table S2), any imbalance would favor controls. Furthermore, 
there were only five cases and seven controls in this category. 
Therefore, this finding was considered unlikely to result in a 
bias in favor of cases.
Cox model hazard ratio analysis (HR)
With regard to baseline variables in the overall population 
(cases+controls), the only significant findings were that females 
survived longer than males in hazard ratio (HR) analysis (P = 
0.043) and that performance score and tumor type affected sur-
vival (P < 0.0001). Time from diagnosis was also significant statis-
tically but not clinically (HR = 0.96 i.e., 10 days).
In the overall population, there was no significant differ-
ence in survival between cases and controls (unadjusted HR = 
1.01). However, since there were subsignificant differences in the 
patient versus control populations, including a higher proportion 
of WHO 2 performance score in cases, and some unevenness 
in the distribution of tumor types as would be expected due to 
chance (Table 1), it was appropriate to adjust for baseline fac-
tors and significant interactions (performance score, tumor type 
and age) with group (cases/controls). Adjustment resulted in a 
rather striking HR of 0.38, which was nevertheless not significant 
(P = 0.088, Table 3), suggesting that the overall population is het-
erogeneous, containing patients that benefit from treatment and 
those that do not.
Table 1 Patient characteristics
Cases  
(n = 270)
Controls 
(n = 186)
Sex (no. of patients)
 Male 113 88
 Female 157 98
Age (years)
 Median 58 63
 Range 3–84 3–87
WHO performance status
 0 25 16
 1 124 101
 2 103 60
 3 18 9
Previous treatments
 Median 3 4
 Range 1–15 0–13
Time from diagnosis (months)
 Median 29 27.5
 Range 3–379 2–235
Tumor type
 Intestinal tumorsa 45 20
 Ovarian cancerb 37 10
 Mesothelial tumorsc 34 13
 Breast cancer 33 22
 Pancreatic cancer 27 22
 Lung cancerd 20 24
 Melanoma 13 4
 Prostate cancer 13 23
 Head and neck cancere 12 4
 Gastric cancerf 10 15
 Urinary tract tumorsg 8 5
 Liver tumorsh 7 12
 Uterine tumorsi 6 5
 Neuroendocrine tumorsj 5 7
aColorectal, small intestinal and anal cancers. bOvarian, fallopian tubal and 
peritoneal cancers. cMesithelioma, sarcoma (all types). dNSCLC but not SCLC. 
eNasopharyngeal, parotic, thyroid and thymus cancers. fGastric and esophageal 
cancers. gRenal and bladder cancers, Wilms tumor. hHepatocellular and chol-
angio cancers. iCervical and endometrial cancers. jNeuroendocrine and adrenal 
cancers, neuroblastoma and SCLC.
Table 2 GMCSF-sensitivity of various cancer types
No of  
patientsa
Disease control 
rate (%)b
GMCSF-sensitive
 Head and neck 13/15 87
 Liver 6/7 86
 Gastric 4/5 80
 Uterine 3/4 75
 Mesothelioma and sarcoma 45/66 68
 Ovarian 23/35 66
 Breast 25/40 48
 Lung 12/28 43
 Melanoma 5/13 38
Non-GMCSF-sensitive
 Urinary tract 1/4 25
 Intestinal 7/34 21
 Pancreatic 3/15 20
 Prostate 1/9 11
 Neuroendocrine 0/2 0
aPatients displaying benefit / analyzed GMCSF virus treated patients.  
bDisease control rate = stable disease or response in imaging analyzes. Tumor 
types featuring >30% disease control rate were categorized as GMCSF  
sensitive.
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Clinical immunotherapy trials typically enroll patients with 
a good performance score. In our case–control study, perfor-
mance score was associated with survival, and extended survival 
was seen in good performance score (WHO 0–1) patients treated 
with oncolytic adenoviruses (P = 0.010), but also in patients with 
more advanced disease (WHO 2) already affecting performance 
(P = 0.0062). No survival advantage was seen in WHO 3 patients. 
Age correlated with survival only in controls, but not in cases, 
suggesting that patients of all ages can benefit from oncolytic 
immunotherapy.
Although the overall ATAP patient population is of reason-
able size for hypothesis generating case–control comparisons 
(N = 270), the caveat in looking at individual tumor types is that 
patient numbers become small and thus statistical power is lost. 
Table 3 Hazard ratio (HR) calculations for overall survival, with confidence intervals (CI), adjusted for baseline factors and significant 
interactions with group (cases/controls)
Effects
All cases and controls (N = 456)
GMCSF sensitive cancer types, treated 
with GMCSF coding virus (N = 257)
GMCSF sensitive cancer types, 
treated with CGTG-102 (N = 201)
P value (Wald) HR and 95% CI P value (Wald) HR and 95% CI P value (Wald) HR and 95% CI
Group (case/control) 0.088 0.38 (0.13, 1.15) 0.23 0.42 (0.10, 1.72) 0.48 0.56 (0.11, 2.83)
Gender (F/M) 0.043 0.77 (0.59, 0.99) 0.25 0.80 (0.55, 1.17) 0.67 0.91 (0.59, 1.39)
Prior radiotherapy (Y/N) 0.19 1.18 (0.92, 1.50) 0.70 0.94 (0.67, 1.31) 0.80 1.05 (0.71, 1.55)
Prior surgery (Y/N) 0.67 1.06 (0.81, 1.38) 0.71 1.07 (0.73, 1.58) 0.90 1.03 (0.65, 1.63)
Time from diagnosis 0.0025 0.96 (0.93, 0.99) 0.021 0.96 (0.93, 0.99) 0.069 0.97 (0.94, 1.00)
Number of previous 
therapies
0.22 0.96 (0.90, 1.02) 0.33 0.96 (0.89, 1.04) 0.065 0.91 (0.83, 1.01)
WHO performance score <0.0001 0.0018 0.0024
WHO/group interaction 0.0010 0.0011 <0.0001
 WHO 0 0.050 0.28 (0.08, 1.00) 0.16 0.31 (0.06, 1.61) 0.34 0.40 (0.06, 2.60)
 WHO 1 0.0034 0.21 (0.07, 0.59) 0.0065 0.15 (0.04, 0.59) 0.022 0.16 (0.03, 0.76)
 WHO 0–1 0.010 0.24 (0.08, 0.71) 0.034 0.22 (0.05, 0.89) 0.095 0.25 (0.05, 1.27)
 WHO 2 0.0062 0.22 (0.07, 0.65) 0.042 0.24 (0.06, 0.95) 0.11 0.25 (0.05, 1.35)
 WHO 3 0.47 1.75 (0.39, 7.96) 0.31 2.77 (0.38, 20.13) 0.11 5.96 (0.65, 54.43)
Age 0.14 0.53 0.50
Age/group interaction 0.0026 0.024 0.058
 Cases 1.07 (0.96, 1.19) 1.10 (0.96, 1.26) 1.09 (0.90, 1.31)
 Controls 0.82 (0.71, 0.94) 0.85 (0.71, 1.02) 0.84 (0.70, 1.01)
Cancer type <0.0001 0.014 0.029
Cancer type/group 
interaction
0.0014 0.0012 0.010
GMCSF sensitive cancer types
 Breast 0.064 0.32 (0.09, 1.07) 0.24 0.40 (0.08, 1.82) 0.40 0.46 (0.08, 2.76)
 Uterine 0.30 0.42 (0.08, 2.15) 0.52 0.54 (0.08, 3.55) 0.88 1.24 (0.07, 22.04)
 Gastric 0.065 0.29 (0.08, 1.08) 0.12 0.27 (0.05, 1.43) 0.41 0.45 (0.07, 3.01)
 Head and Neck 0.004 0.10 (0.02, 0.47) 0.039 0.14 (0.02, 0.90) 0.16 0.23 (0.03, 1.81)
 Liver 0.27 0.44 (0.10, 1.90) 0.66 0.68 (0.12, 3.79) 0.94 0.93 (0.13, 6.77)
 Lung 0.092 0.33 (0.09, 1.20) 0.24 0.39 (0.08, 1.91) 0.31 0.40 (0.07, 2.34)
 Melanoma 0.28 2.66 (0.46, 15.54) 0.19 3.60 (0.53, 24.57) 0.27 3.21 (0.41, 25.07)
  Mesothelioma and 
Sarcoma
0.28 0.54 (0.18, 1.66) 0.47 0.60 (0.15, 2.38) 0.63 0.67 (0.14, 3.29)
 Ovarian 0.0003 0.08 (0.02, 0.29) 0.0059 0.09 (0.02, 0.49) 0.024 0.11(0.02, 0.75)
Non-GMCSF sensitive cancers
 Intestinal 0.070 0.32 (0.09, 1.10)
 Neuroendocrine 0.98 0.98 (0.20, 4.87)
 Pancreatic 0.064 0.29 (0.08, 1.08)
 Prostate 0.31 0.47 (0.11, 2.03)
 Urinary Tract 0.63 0.67 (0.13, 3.47)
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Nevertheless, as such preliminary analyses might be useful for the 
purpose of identifying candidate trial populations, preplanned 
exploratory examination of different tumor types was performed. 
In Cox model analysis of survival, ovarian cancer (P = 0.0003) and 
squamous cell cancer of the head and neck (P = 0.004) stood out 
with HRs of 0.08 and 0.10 (Table 3). The number of cases was low 
in the latter group and thus chance could have played a role but 
there were 37 ovarian cancer patients rendering this into a tan-
talizing finding. In GMCSF virus treated patients, HRs were also 
low for these two tumor types (HR = 0.09 for ovarian, P = 0.0059; 
HR = 0.14, P = 0.039 for head and neck). With CGTG-102, only 
ovarian was significant (P = 0.024, HR = 0.11).
Kaplan–Meier analysis
Since cases and controls were rather well balanced overall (Table 1, 
Supplementary Table S2), we proceeded to Kaplan–Meier sur-
vival analysis which has the benefit of yielding median survival 
figures, useful for estimating clinical relevance in addition to 
statistical significance. The comparison of overall survival was 
done first for all patients (N = 270) versus all controls (N = 186) 
and as in unadjusted HR analysis, there was no significant differ-
ence (Figure 1a, Breslow’s test P = 0.793). Next, we looked at all 
patients (N = 197) that had received GMCSF-expressing viruses 
and although now median survival was 25 days longer in cases 
than controls, the difference was not significantly different sug-
gesting that in an unselected population GMSCF-armed viruses 
have limited or no effect on overall survival (P = 0.128, Figure 1b). 
However, when we focused on patients with GMCSF-sensitive 
cancer types (Table 2), treated with GMCSF-coding viruses (N = 
148), the median survival benefit was 38 days (22%) and statisti-
cally significant (Breslow’s P = 0.034, Figure 1c).
Next, we focused on a typical trial population featuring good 
performance score (WHO 0–1), GMCSF-sensitive tumor types 
and treatment with a GMCSF-coding virus (N = 90). In these 
patients, median survival was 99 days longer in virus treated 
patients (Breslow’s P = 0.040, Figure 1e), constituting a 51% 
increase in median overall survival, which is significant not only 
statistically but also clinically.
In order to avoid confounding due to different viruses, we per-
formed an analysis restricted to a single virus, CGTG-102, and 
median survival of patients with GMCSF-sensitive tumor types 
(N = 92) was 247 days versus 170 days in controls, constituting a 
77 days (45%) increase in median overall survival (Breslow’s P = 
0.017, Figure 1f). Finally, to focus on an anticipated trial popu-
lation, CGTG-102 treated patients with good performance score 
(WHO 0–1) and GMCSF sensitive tumors (N = 60) featured a 
median survival of 326 days, a 69% improvement over 193 days in 
controls (133 days, Breslow’s P = 0.022, graph not shown).
Figure 1 Cumulative survival data. Virus treated patients = black line, control patients = gray line. (a) All viral treatments pooled. (b) All patients 
treated with GMCSF-coding viruses. (c) Patient with GMCSF-sensitive cancer types and treatment with GMCSF-coding viruses. (d) Patients with WHO 
performance status 0 or 1. (e) Patients with good performance score (WHO 0 or 1), GMCSF-sensitive tumor types and treatment with a GMCSF-
coding virus. (f) Subpopulation of patients with GMCSF-sensitive cancer types and treatment with CGTG-102 virus.
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Recognizing the risk that with small case and control numbers 
chance can impact survival comparisons, we nevertheless pro-
ceeded with preplanned evaluation of tumor types, as this might 
guide in trial design. Focusing on cancers where at least 10 cases 
and controls were available, the only group with a significant dif-
ference in overall survival was ovarian cancer patients. Cases (N = 
37) survived 180 days longer than controls, constituting a promis-
ing 240% increase in survival (Breslow’s P < 0.001, Figure 2a).
With ovarian cancer emerging as an interesting patient group, 
we further studied the cases in more detail. The 37 cases consisted of 
28 ovarian, 6 fallopian tubal, and 3 primary peritoneal carcinomas. 
Treatment was generally well tolerated, and no mortality occurred, 
although 12 patients did experience grade 3 adverse events, of which 
intestinal problems were the most common (Figure 2c). There were 
no grade 4 or 5 adverse events. The overall disease control rates were 
56 and 55% with imaging (RECIST1.1 or PET criteria) and CA125 
tumor marker analysis, respectively (Figure 2d). The median sur-
vival for all ovarian cancer patients was 254 days, which compares 
favorably not only to the controls of this study, but also to historical 
data with similarly heavily pretreated patient populations.17,18
Focusing on ovarian cancer patients treated with CGTG-102, 
median overall survival was 337 days in patients (N = 23) and 74 
days in controls, constituting a 355% improvement in overall sur-
vival (Breslow’s P < 0.001, Figure 2b). Furthermore, as previous 
data suggests that multiple treatment may be advantageous over 
a single virus injection12 this was assessed also in these patients. 
There was a statistically significant difference in favor of multiple 
injections of virus (P = 0.030, Figure 2e).
DISCUSSION
Oncolytic viruses armed with immunostimulatory transgenes 
are an emerging treatment approach for tumors incurable with 
available modalities. However, only one randomized phase 3 trial 
has been completed, featuring a herpes virus armed with GMCSF 
(T-Vec). This trial met its primary endpoint of durable response 
rate and also progression free survival was dramatically increased, 
but most importantly, the overall survival was ca. 4.5 months in 
favor of T-Vec (P = 0.051).19 Perhaps of relevance, as presented at 
ASCO 2014, a final overall survival analysis, with mature data, is 
pending in late 2014 or early 2015.19
Figure 2 Patients with ovarian, fallopian tubal and primary peritoneal carcinomas. (a) Cumulative survival data of all ovarian cancer patients ana-
lyzed. Virus treated patients = black line, control patients = gray line. (b) Subgroup of ovarian cancer patients treated with CGTG-102 virus. (c) Grade 
3 adverse events in ovarian cancer patients treated with oncolytic adenoviruses. (d) Clinical responses in ovarian cancer patients after viral treatments. 
(e) Overall survival of ovarian cancer patients with single or serial viral treatments. Serial treatment = black line, single treatment = gray line.
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However, because the T-Vec trial is the only available phase 3 
where overall survival was assessed, albeit as a secondary endpoint 
in a 436 patient trial not powered for survival comparisons, it is 
interesting to compare their results to ours, keeping in mind that 
the T-Vec trial was randomized while our study is nonrandom-
ized. In analysis of the overall population, their HR was 0.79 (P = 
0.051) while our adjusted HR was 0.38 (P = 0.088). In subgroup 
analysis, T-Vec improved survival significantly when it was given 
as a first line therapy (HR = 0.50, P < 0.001) in Stage IIIB/C and 
IVM1a melanoma (HR = 0.57, P < 0.001), but not in more bulky 
Stage IVM1b/c disease (HR = 1.07).19 Seemingly in parallel, in our 
analysis significant differences in survival were only seen when 
the population was restricted to tumor types sensitive to GMCSF 
or to good performance score patients.
There is no doubt that well-designed large randomized phase 
3 trials are needed to reliably demonstrate a survival advan-
tage. However, in the absence of such trials, it may be of inter-
est to attempt to obtain preliminary data using an observational 
approach such as the case–control design. Case–control studies 
have traditionally been employed to gain preliminary informa-
tion on efficacy of treatments, estimate the magnitude of benefits 
if present, and to form hypotheses on patient populations likely 
to benefit.
The well-known caveats of case–control series relate to the 
difficulty of selecting appropriate controls. This, however, can be 
assessed by comparing the distribution of baseline characteristics 
of the study groups. In our study, the cases and the controls were 
well matched. The controls were somewhat older but, on the other 
hand, the cases were more heavily pretreated which might coin-
cide with more advanced disease. At individual sites, the effect 
of age was only noted for neuroendocrine and ovarian tumors, 
both of borderline significance. Five-year net survival is highest 
in the youngest adults for nearly all cancers, with survival gener-
ally decreasing with increasing age.20 On one hand, older patients 
may respond less well to immunotherapy, but on the other it is 
known that cancer arising in younger individuals can behave in 
a particularly aggressive manner.21,22 The same uncertainty exists 
for number of previous treatments received prior to oncolytic 
virus. While more pretreatment may mean that the tumor is more 
refractory, more evolved, and may be further advanced and thus 
more aggressive than less treated tumors, one could also argue that 
heavily pretreated tumors may have been initially less aggressive 
than tumors that couldn’t be heavily treated because the patient 
expired rapidly due to tumor progression.
However, since the differences were small in this study, 
we feel that neither aspect impacts the analyses performed. 
Importantly, the most important prognostic factors were well 
balanced: performance score, sex, tumor types, and time from 
diagnosis. The lack of imbalance between groups seems to be 
supported by the fact that there was no difference in survival 
of the overall case and control populations. In fact, the median 
survival of cases was slightly less than controls suggesting that 
if anything, the baseline characteristics were “in favor” of the 
controls, perhaps due to more WHO 2 patients among cases. 
This was confirmed with hazard ratio analysis where improved 
survival was seen in performance score classes WHO 0 (border-
line), WHO 1, and WHO 2.
Interestingly, when we focused on tumor types possibly sensi-
tive to viruses armed with GMCSF, a significant survival advan-
tage was seen for patients treated with GMSCF-coding viruses. 
Conversely, this implies that not all tumors are sensitive to 
GMCSF-mediated oncolytic immunotherapy. Like all cytokines, 
GMCSF is a double edged sword immunologically. In classic stud-
ies, it was initially reported as the most potent stimulator of anti-
tumor immunity23 and therefore it has become popular in various 
cancer vaccination and immunotherapy approaches. Although 
we had a suspicion that some tumor types are more sensitive to 
GMCSF-mediated immunotherapy than others, the grouping into 
“GMSCF-sensitive” or not, was somewhat exploratory. However, 
it seemed to be validated by the data presented in this manuscript. 
Specifically, when patients were grouped by imaging response 
(Table 2), subsequent prospective (and blinded) analysis of sur-
vival seemed to be in accord with the notion of some tumor types 
being more “GMCSF sensitive” than others. While considering 
this hypothesis, which will require randomized trials for proof, 
it is noteworthy that imaging and survival are not automatically 
linked in proinflammatory immunotherapy, to the same degree as 
with classic tumor therapies.15,16,24
GMCSF has effects on antigen presenting cells and natural 
killer cells. However, GMCSF stimulates also myeloid derived 
suppressor cells (MDSC).25 One could speculate that the rea-
son why some tumor types seem sensitive to GMCSF and some 
do not, could relate to the relative importance of stimulation of 
antigen presentation and the counterproductive effects of MDSC 
recruitment. However, much further studies are required in this 
regard. Also, within tumor types there could be significant varia-
tion between individuals. These studies are incredibly challeng-
ing as many different cell types are involved. In intact organisms, 
immune cells are constantly morphing from suppressive to immu-
nostimulatory subtypes and local effects probably do not correlate 
with effects seen in blood, which is just “the highway” for cells 
whose activity is local.12 Biopsies reflect a snapshot of a complex, 
constantly changing phenomena occurring over weeks, months 
and years. Also, biopsies can only reveal information from the 
biopsy location.
Nevertheless, our understanding of MDSC and the immune 
system in general is developing rapidly, yet we may not know 
enough of the relevant cell types to fully understand why GMCSF-
based immunotherapy works in some animal models or patients 
while not in others. Our data presented here suggests that some 
tumor types are more likely to respond to GMCSF-based immu-
notherapy. Some preclinical and clinical evidence suggest that 
GMCSF expression in pancreatic cancer might have a dismal 
role.26,27 Corresponding features were seen in our study with pan-
creatic cancer having only 20% (3/15) response rate. Nevertheless, 
it seems clear that advantageous or disadvantageous immuno-
logical profiles may not be tumor type specific. Instead, it seems 
likely that each tumor will be an individual in this regard. One 
could speculate that Amgen’s T-Vec result is in accord with this 
notion; nonbenefiting patients had bulkier disease19 which could 
also mean more MDSC.28 However, while the molecular details 
of the GMCSF-sensitive phenotype are being worked out, the 
clinical evaluation presented here can be helpful in focusing 
the first generation of trials. With regard to GMCSF mediated 
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immunotherapy, it would be of critical importance to understand 
better the possible links between MDSC induction and tumor 
progression, and the differences, if any, between different tumor 
types.
Thus, while mouse studies are critically important for hypoth-
esis generation and testing in oncology, immunology and immu-
notherapy, the human data obtainable from patient biopsies is 
of critical importance. Clinical trials can be prohibitively expen-
sive to initiate. Thus, any data that can be helpful in designing a 
successful trial is most welcome. In this regard, we feel the case–
control approach can have merit. While case–control compari-
sons cannot prove anything, they may lend support to patient 
selection and provide general enthusiasm (“reasons to believe”) 
for performing a randomized trial.
To summarize our key findings, we did not see improve-
ment in median survival when all 270 patients were compared 
to the matched controls. However, when analysis was restricted 
to GMCSF-sensitive tumor types treated with GMCSF-coding 
viruses, a significant survival advantage was seen. When only 
good performance score patients were included, the survival 
advantage increased further. When focusing on a single virus, 
CGTG-102, which is currently being studied in clinical trials by 
Oncos Therapeutics, a survival advantage was seen in GMCSF-
sensitive tumor types, and the magnitude of the benefit was great-
est in WHO 0–1 patients. In hazard ratio analysis, which takes 
into account even nonsignificant imbalances between groups, 
treatment benefits were evident in WHO classes 0–2.
There is no doubt that a 69% improvement in median overall 
survival, from 193 to 326 days, is significant not only statistically 
but also clinically. As reported previously, three rounds of treat-
ment were more effective than a single injection. By extension, 
and taking into account that most patients treated in the ATAP 
progressed while off therapy, it would be interesting to see if effi-
cacy would be further improved with longer treatment.
With regard to individual tumor types, we remain cautious 
of interpreting the data based on small patient numbers. Thus, 
although there seem to be some parallels between our “GMCSF sen-
sitive” tumor types and the number of mutations reported for dif-
ferent tumors (which has been proposed to as a partial explanation 
for sensitivity to immunotherapy),29 the case numbers are too small 
to draw any conclusions. However, preplanned exploratory analy-
ses highlighted ovarian cancer as an interesting choice for inclusion 
in clinical trials. Nevertheless, it may be of relevance that grade 3 
abdominal adverse events were frequently seen in these patients. 
As ileus and abdominal pain are common in patients with perito-
neally disseminated cancer, caused both by the adhesive effects of 
carcinomatosis and the after-effects of often multiple operations, 
the association of these events with oncolytic adenovirus treatment 
deserves further study. If there is association, it is interesting to study 
if the same mechanisms that contribute to adverse events also play a 
role in efficacy. For example, T cells and NK cells kill tumor cells by 
releasing perforin and other and granzymes and proteases.30 Given 
the intimate association of ovarian carcinomatosis with the nerves 
covering intestines, the aforementioned molecules might affect also 
normal tissues and might explain the adverse events experienced. 
Also, transient swelling of these gut-lining tumor lesions after 
immunotherapy might result in physical distension.
It does not come as a surprise that ovarian cancer patients 
might benefit from oncolytic immunotherapy. Although this tumor 
type has traditionally not been among the classic “immune sensi-
tive” cancers, there is evidence of anti-tumor immune responses 
in patients, as exemplified by the frequent presence of tumor infil-
trating lymphocytes.31,32 A practical advantage is that virus can be 
applied directly into the peritoneal cavity, increasing local versus 
systemic concentrations. Also, the peritoneal cavity can be seen as a 
giant immunological organ with easy access by immune cells, com-
plement and antibodies through the peritoneal lining.33,34 Moreover, 
given frequent presentation as cavity-lining carcinomatosis, instead 
of large immunosuppressive tumor masses, suppressive mecha-
nisms could be less daunting than with some other tumors.
In conclusion, the case–control comparison presented here 
suggests that good performance score patients with certain tumor 
types survived longer subsequent to oncolytic immunotherapy 
with GMCSF-coding oncolytic adenoviruses. These results lend 
support to randomized clinical trials with GMCSF-coding onco-
lytic viruses.
MATERIALS AND METHODS
Treatments. Treatments were given in the context of ATAP in Docrates 
Hospital, Helsinki, Finland, between 2007–2011.1–14 ATAP is a personal-
ized therapy approach, not a clinical trial, and the treatments are based on 
Article 37 (previously Article 35 and initially Article 32) of World Medical 
Association Declaration of Helsinki. The general inclusion criteria for treat-
ment in ATAP were: solid tumors refractory to conventional therapies, pro-
gressive disease, WHO performance score ≤3 and no major organ function 
deficiencies. General exclusion criteria were: organ transplant, HIV or other 
major immunosuppression, known brain metastasis, elevated bilirubin, 
ALT or AST elevated ×3 upper limit of normal, severe thrombocytopenia 
and other severe disease or organ malfunction. All patients signed writ-
ten informed consent. A total of 290 patients were treated in ATAP, 270 of 
which had survival information available, and could thus be included in this 
study (Table 1). Survival information was collected from medical records 
and updated through the Finnish Population Registry for Finnish patients.
The oncolytic viruses administered to patients in ATAP were regulated 
by Regulation (EC) No 1394/2007 on advanced therapy medicinal 
products, amending Directive 2001/83/EC and Regulation (EC) No 
726/2004. According to EC/1394/2007, manufacturing of advanced therapy 
medicinal products shall be authorized by the competent authority of the 
Member State. The competent authority authorizing the manufacturing of 
the products administered in ATAP is Finnish Medical Agency (FIMEA). 
FIMEA also requires reporting of adverse reactions. The Helsinki 
University Central Hospital Operative Ethics committee has rendered a 
favorable opinion on this case–control study (62/13/03/02/2013).
Individually tailored treatments were performed intratumorally 
in ultrasound or CT guidance, intravenously, or as an intraperitoneal 
or intrapleural injection as published.1–14 Patients were monitored for 
24 hours in the hospital and for 4 weeks as outpatients. Viruses used 
for treatments have been published previously1–14 and are listed in 
Supplementary Table S1. Of note, GMCSF and GM-CSF indicate the 
same molecule. The definition for serial treatment is three rounds of 
oncolytic adenovirus within 10 weeks; treatments not fulfilling this 
criterion were evaluated as single treatments.12 The decision of the number 
of injections was done on a patient-by-patient basis. The length of survival 
or low WHO classification did not automatically increase it.
Analysis of treatment efficacy. RECIST 1.1 criteria were applied to overall 
disease status including injected and noninjected tumors. In some cases, 
PET-CT was used instead of conventional CT, using published criteria,24 in 
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which the five most active lesions, maximum two lesions per organ, were 
evaluated for SUVmax and the values were summed. Progressive meta-
bolic disease indicates more than 30% increase in summed SUVmax or 
≥2 cm PET positive new lesion. Stable metabolic disease indicates −29 to 
+29% change, partial metabolic response notes more than 30% decline in 
summed SUVmax. Complete metabolic response = disappearance of all 
metabolically active tumor. Tumor markers (e.g., CA125) were measured 
from serum when elevated at baseline. Overall survival was calculated 
from the initial oncologist appointment until death.
Control patients. Matched controls were selected from all patients treated 
at the same hospital during the same time interval (2007–2011). Some 
grouping by organ was performed to allow analysis of also rarer tumor 
types (Table 1), followed by group matching by cancer type and phase of 
the disease, the latter indicating that these patients were refractory to rou-
tinely used standard therapies as was the case for ATAP patients. Controls 
were selected first and survival data was collected afterwards. 186 control 
patients fulfilling these criteria were found. Refractory disease was defined 
as follows for different tumor types:
-   Ovarian: relapse within 6 months from first line chemotherapy or 
progression after second line chemotherapy
-   Metastatic soft tissue sarcoma, melanoma, pancreatic, gastric, 
esophageal, head and neck, anal, cervical, hepatocellular, bladder, 
mesothelioma, neuroendocrine tumors progressing after first line 
chemotherapy
-   Metastatic colorectal cancer progressing subsequent to irinotecan 
and oxaliplatin therapy
-   Renal: progressing after second line chemotherapy
-   Metastatic breast cancer progressing after chemotherapy with an-
thracyclines and taxanes
-   Lung cancer: progressing or persistent after first line chemotherapy
-   Advanced or metastatic prostate cancer progressing after treatment 
with taxanes
-   Cholangiocarcinoma and “other” tumors: progressing or persistent 
after treatment with evidence-based oncological therapy
Statistical analysis. Statistics were done with SPSS v15.0 (SSPS, Chicago, 
IL). First, baseline variables that might have had an impact on overall 
survival were evaluated. Continuous and ordinal variables (WHO per-
formance score, age, time from initial diagnosis and number of previous 
regimen) were analyzed with Mann–Whitney U-test, while for categorical 
variables (sex, prior radiation therapy and surgery) Fisher’s exact test was 
used. For both tests, a significance value of P < 0.05 was interpreted as a sta-
tistically significant difference. In the case of unevenly distributed variables, 
log rank-test was used. Hazard ratios (HRs) were calculated according to 
the Cox proportional hazards model. Survival data was also processed with 
Kaplan–Meier analysis and Breslow’s (generalized Wilcoxon) test.
Cox proportional hazard model was applied with focus on comparison 
between cases and controls but adjusting for baseline factors and their 
possible interactions with the grouping term (cases and controls). The 
final model contained all baseline factors (gender, previous radiotherapy, 
time from diagnosis, number of previous therapies, WHO performance 
score, age, and cancer type) and statistically significant interactions 
with group (WHO performance score, age, and cancer type). The same 
model was repeated with a subgroup of GMCSF sensitive cancer types, 
and with CGTG-102 treated patients. The assumption of proportionality 
was assessed by inclusion of time dependent covariates in the model. Cox 
model calculations were performed with SAS version 9.3.
SUPPLEMENTARY MATERIAL
Table S1. List of viruses used.
Table S2. Log-rank P-values for comparison of survival in cases and 
controls: all patients
Table S3. Log-rank P-values for comparison of survival in cases and 
controls: GMCSF treated patients.
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